324 related articles for article (PubMed ID: 23334105)
1. Down Syndrome: what do pregnant women know about their individual risk? A prospective trial.
Strauss A; Heer IM; Spelsberg F; Strauss C
Arch Gynecol Obstet; 2013 Jun; 287(6):1119-23. PubMed ID: 23334105
[TBL] [Abstract][Full Text] [Related]
2. [Study on key techniques and intervention in reducing birth defects].
Zhu BS; Su J; Lu XH; He J; Zhu S; Jiao CX; Zhang JM; Tang XH; Tao Y; Lin KP; Chen H; Li SY
Zhonghua Fu Chan Ke Za Zhi; 2011 Sep; 46(9):658-63. PubMed ID: 22176989
[TBL] [Abstract][Full Text] [Related]
3. Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination.
Dick PT
CMAJ; 1996 Feb; 154(4):465-79. PubMed ID: 8630836
[TBL] [Abstract][Full Text] [Related]
4. Perceived risk of prenatal diagnostic procedure-related miscarriage and Down syndrome among pregnant women.
Caughey AB; Washington AE; Kuppermann M
Am J Obstet Gynecol; 2008 Mar; 198(3):333.e1-8. PubMed ID: 18177830
[TBL] [Abstract][Full Text] [Related]
5. [Value of detection of cell-free fetal DNA in maternal plasma in the prenatal diagnosis of chromosomal abnormalities].
Wang SJ; Gao ZY; Lu YP; Li YL; You YQ; Zhang LW; Wang LX; Xu H
Zhonghua Fu Chan Ke Za Zhi; 2012 Nov; 47(11):808-12. PubMed ID: 23302119
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
[TBL] [Abstract][Full Text] [Related]
7. [Karyotype analysis of amniotic fluid cells and comparison of chromosomal abnormality rate during second trimester].
Zhang YP; Wu JP; Li XT; Lei CX; Xu JZ; Yin M
Zhonghua Fu Chan Ke Za Zhi; 2011 Sep; 46(9):644-8. PubMed ID: 22176986
[TBL] [Abstract][Full Text] [Related]
8. [Serum screening of fetal chromosome abnormality during second pregnancy trimester: results of 26,803 pregnant women in Jiangsu Province].
Hu YL;
Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(35):2476-80. PubMed ID: 18067809
[TBL] [Abstract][Full Text] [Related]
9. How important is consent in maternal serum screening for Down syndrome in France? Information and consent evaluation in maternal serum screening for Down syndrome: a French study.
Favre R; Duchange N; Vayssière C; Kohler M; Bouffard N; Hunsinger MC; Kohler A; Mager C; Neumann M; Vayssière C; Viville B; Hervé C; Moutel G
Prenat Diagn; 2007 Mar; 27(3):197-205. PubMed ID: 17238219
[TBL] [Abstract][Full Text] [Related]
10. Uptake of invasive prenatal diagnostic tests in women after detection of soft markers for chromosomal abnormality on ultrasonographic evaluation.
Sharda S; Phadke SR
J Perinatol; 2007 Sep; 27(9):550-5. PubMed ID: 17611609
[TBL] [Abstract][Full Text] [Related]
11. Screening for Down syndrome: practice patterns and knowledge of obstetricians and gynecologists.
Cleary-Goldman J; Morgan MA; Malone FD; Robinson JN; D'Alton ME; Schulkin J
Obstet Gynecol; 2006 Jan; 107(1):11-7. PubMed ID: 16394034
[TBL] [Abstract][Full Text] [Related]
12. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
Spencer K; Bindra R; Cacho AM; Nicolaides KH
Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
[TBL] [Abstract][Full Text] [Related]
13. [Prenatal diagnosis].
Miny P; Tercanli S; Gänshirt D; Holzgreve W
Ther Umsch; 1995 Dec; 52(12):792-800. PubMed ID: 8539649
[TBL] [Abstract][Full Text] [Related]
14. [Relationship of adverse pregnancy outcomes and a high risk serum screen for Down syndrome in the second trimester].
Hu XY; Bian XM; Jiang YL; Liu SY
Zhonghua Fu Chan Ke Za Zhi; 2012 Jun; 47(6):427-30. PubMed ID: 22932108
[TBL] [Abstract][Full Text] [Related]
15. First-trimester Down syndrome screening: pregnant women's knowledge.
Dahl K; Hvidman L; Jørgensen FS; Henriques C; Olesen F; Kjaergaard H; Kesmodel US
Ultrasound Obstet Gynecol; 2011 Aug; 38(2):145-51. PubMed ID: 20878670
[TBL] [Abstract][Full Text] [Related]
16. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years.
Biggio JR; Morris TC; Owen J; Stringer JS
Am J Obstet Gynecol; 2004 Mar; 190(3):721-9. PubMed ID: 15042005
[TBL] [Abstract][Full Text] [Related]
17. Assessment of maternal anxiety levels before and after amniocentesis.
Ng CC; Lai FM; Yeo GS
Singapore Med J; 2004 Aug; 45(8):370-4. PubMed ID: 15284930
[TBL] [Abstract][Full Text] [Related]
18. Recurrences of free trisomy 21: analysis of data from the National Down Syndrome Cytogenetic Register.
Morris JK; Mutton DE; Alberman E
Prenat Diagn; 2005 Dec; 25(12):1120-8. PubMed ID: 16231400
[TBL] [Abstract][Full Text] [Related]
19. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.
Haddow JE; Palomaki GE; Knight GJ; Cunningham GC; Lustig LS; Boyd PA
N Engl J Med; 1994 Apr; 330(16):1114-8. PubMed ID: 7510852
[TBL] [Abstract][Full Text] [Related]
20. Do women know that prenatal testing detects fetuses with Down syndrome?
Jaques AM; Halliday JL; Bell RJ
J Obstet Gynaecol; 2004 Sep; 24(6):647-51. PubMed ID: 16147604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
